Who Should Monitor for Tysabri-Related PML? A Case Review

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Legal Concerns

If you or a loved one is taking Tysabri, understanding the early signs of progressive multifocal leukoencephalopathy (PML) is critical. Decades of pharmacovigilance and case reports have established a clear pattern linking prolonged Tysabri use to PML risk, particularly in patients with certain co-factors. This page reviews the documented risk factors and monitoring guidelines to help you make informed decisions.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn disease in adults. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and Tysabri-treated patients are at elevated risk due to the drug's mechanism of action, which involves blocking lymphocyte trafficking to the central nervous system, thereby reducing immune surveillance against JCV reactivation. Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML, and the risk increases with cumulative exposure to the drug. The boxed warning emphasizes that healthcare professionals should monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML and that Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Adverse Event Reports

The clinical presentation of PML is variable and can include progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, visual changes, and speech difficulties. These symptoms overlap with those of multiple sclerosis relapses, which can delay diagnosis. In the FDA Adverse Event Reporting System (FAERS), adverse events most frequently associated with Tysabri include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), asthenia (7,852 reports), balance disorder (5,621 reports), muscular weakness (4,535 reports), cognitive disorder (3,478 reports), and mobility decreased (3,769 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they reflect the spectrum of neurological symptoms that may be associated with PML or other Tysabri-related adverse effects. The mechanistic pathway linking Tysabri to PML involves the drug's inhibition of alpha-4 integrin, which prevents lymphocytes from crossing the blood-brain barrier. This reduces immune surveillance in the central nervous system, allowing latent JCV to reactivate and infect oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is highest in patients with anti-JCV antibodies, as these antibodies indicate prior JCV exposure and potential viral reactivation.

Legal Considerations for Florida Patients

For patients in Florida who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a claim. In Florida, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For medical malpractice or product liability claims involving Tysabri, the timeline may begin when the patient or their family becomes aware of the link between the drug and PML. Given that PML symptoms can be subtle and may initially be attributed to multiple sclerosis progression, the date of discovery can be complex. Patients and their families should consult with an attorney experienced in pharmaceutical litigation to determine the applicable deadline for their specific case. The adequacy of warnings regarding Tysabri and PML is a central issue in potential litigation. The prescribing information includes a boxed warning that clearly states the increased risk of PML and identifies known risk factors. However, questions may arise about whether healthcare providers and patients were adequately informed about the magnitude of the risk, the need for regular monitoring, and the importance of withholding treatment at the first sign of PML. The TOUCH Prescribing Program is designed to ensure that patients are informed of the risks, but program compliance and communication effectiveness may vary.

Timeline of Exposure and Harm

The timeline between Tysabri exposure and documented harm is critical for both medical management and legal claims. PML can develop months to years after starting Tysabri, with risk increasing after two years of treatment. Early diagnosis and prompt discontinuation of Tysabri are essential to improve outcomes, but even with treatment, PML often leads to severe disability or death. Patients who develop PML may require intensive supportive care, including antiviral therapy and rehabilitation. In summary, Tysabri is associated with a well-documented risk of PML, which is a serious and often fatal brain infection. Patients in Florida who have been harmed by PML after Tysabri treatment should be aware of the statute of limitations for filing a claim and should seek legal counsel to evaluate their options. The evidence from FDA labeling and adverse event reports underscores the importance of risk awareness and timely intervention.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Florida?

In Florida, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. For Tysabri-related PML claims, this timeline may begin when the patient or their family becomes aware of the link between the drug and PML. It is crucial to consult with an attorney experienced in pharmaceutical litigation to determine the exact deadline for your case.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and the risk increases with cumulative exposure to the drug.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.